Alamar Biosciences Inc

ALMR

Company Profile

  • Business description

    Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.

  • Contact

    47071 Bayside Parkway
    FremontCA94538
    USA

    T: +1 510 626-9888

    https://www.alamarbio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Devices

    Fiscal Year End

    31 December 2026

    Employees

Stocks News & Analysis

stocks

Avoid this overvalued ASX healthcare share

Expensive healthcare share limited by its core addressable market.
stocks

AI driving growth for ASX tech share

ASX tech share raises funds to facilitate customer AI spend.
stocks

OpenAI is going public as the worst value among its peers

Investors are paying a steep price relative to the underlying business quality, PitchBook research says.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,824.8067.500.77%
CAC 408,203.434.140.05%
DAX 4024,433.06183.16-0.74%
Dow JONES (US)50,872.1186.100.17%
FTSE 10010,227.33145.87-1.41%
HKSE24,565.9091.16-0.37%
NASDAQ25,678.82250.84-0.97%
Nikkei 22565,416.631,392.032.17%
NZX 50 Index13,143.8260.26-0.46%
S&P 5007,386.6519.08-0.26%
S&P/ASX 2008,604.2070.700.83%
SSE Composite Index4,010.0350.691.28%

Market Movers